A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation

Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/10274

Title:	A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation
Authors:	Davies, J.C. Sermet-Gaudelus, I. Naehrlich, L. Harris, R.S. Campbell, D. Ahluwalia, N. Short, C. Haseltine, E. Panorchan, P. Saunders, C. Owen, C.A. Wainwright, C.E.
Issue Date:	2021
Journal:	Journal of Cystic Fibrosis
Appears in Sites:	Publication workflow Queensland Health Publications

22

checked on Jul 17, 2025

Check